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The ancestral glycoprotein hormone thyrostimulin is a heterodimer of unique glycoprotein hor-
mone subunit alpha (GPA)2 and glycoprotein hormone subunit beta (GPB)5 subunits with high
affinity for the TSH receptor. Transgenic overexpression of GPB5 in mice results in cranial abnor-
malities, but the role of thyrostimulin in bone remains unknown. We hypothesized that thyro-
stimulin exerts paracrine actions in bone and determined: 1) GPA2 and GPB5 expression in osteo-
blasts and osteoclasts, 2) the skeletal consequences of thyrostimulin deficiency in GPB5 knockout
(KO) mice, and 3) osteoblast and osteoclast responses to thyrostimulin treatment.Gpa2 andGpb5
expressionwas identified in thenewborn skeletonbut declined rapidly thereafter.GPA2 andGPB5
mRNAs were also expressed in primary osteoblasts and osteoclasts at varying concentrations. Ju-
venile thyrostimulin-deficient mice had increased bone volume and mineralization as a result of
increased osteoblastic bone formation. However, thyrostimulin failed to induce a canonical cAMP
response or activate the noncanonical Akt, ERK, or mitogen-activated protein kinase (P38) signal-
ing pathways in primary calvarial or bone marrow stromal cell-derived osteoblasts. Furthermore,
thyrostimulin did not directly inhibit osteoblast proliferation, differentiation or mineralization in
vitro. These studies identify thyrostimulin as a negative but indirect regulator of osteoblastic bone
formation during skeletal development. (Endocrinology 156: 3098–3113, 2015)
Glycoprotein hormones have a central role in regula-tion of the hypothalamic-pituitary-thyroid and hy-
pothalamic-pituitary-gonadal axes. The glycoprotein
hormones TSH, LH, FSH, and chorionic gonadotropin
(CG) are heterodimeric proteins formed by the nonco-
valent association of a common -subunit and a unique
-subunit that confers hormonal specificity. Thyro-
stimulin is a novel glycoprotein hormone recently
identified as a result of homology to the cysteine-knot
motif characteristic of the glycoprotein hormone and
TGF- superfamilies (1). In contrast to the known gly-
coprotein hormones thyrostimulin is formed from a het-
erodimer of unique - and -subunits, glycoprotein
hormone subunit alpha (GPA)2 and glycoprotein hor-
mone subunit beta (GPB)5, and is highly conserved
across species.
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Glycoprotein hormones act via type A leucine-rich re-
peat-containing G protein-coupled receptors (2, 3) and
recombinant thyrostimulin has been shown to have high
affinity for the TSH receptor (TSHR) (1). Indeed, human
thyrostimulin is 4-fold more potent than human TSH at
inducing a TSHR-mediated cAMP response (1, 4),
whereas glycosylation of both GPA2 and GPB5 subunits
are essential for secretion and activity of thyrostimulin (5,
6). Despite this, 100-fold higher concentrations of GPB5
alone can also induce a TSHR-mediated cAMP response
(4).
Phylogenetic studies demonstrated that GPA2 and
GPB5 encode ancestral glycoprotein hormone subunits
that originated before the divergence of nematodes, ar-
thropods and vertebratesmore than 1 billion years ago (3,
7–9).GPA2 andGPB5 are, therefore, present in both ver-
tebrates and invertebrates and thought to have given rise
to the vertebrate common -subunit (glycoprotein hor-
mone ) and unique -subunits (TSH, LH, and FSH)
by gene duplication (10, 11).
Thyrostimulin expression has been investigated in sev-
eral species (1, 4, 7, 12–14), and, in common with other
glycoprotein hormones, GPA2 and GPB5 were initially
found to be coexpressed in the pituitary (1, 4, 13). How-
ever, studies inDrosophila melanogaster,Caenorhabditis
elegans, Amphioxus, and mouse indicated a broader de-
velopmental role for GPA2 and GPB5 (5, 15–17) and also
suggested the subunits might act independently as mono-
mers or homodimers (5). Furthermore, GPB5 lacks the
conserved “seatbelt” motif considered necessary for gly-
coprotein hormone heterodimer stability in the circula-
tion. Taken together, these findings indicate that GPA2/
GPB5 heterodimersmay predominantly exist at local sites
of coexpression and thus suggest a paracrine rather than
endocrine role for thyrostimulin (7, 18). Accordingly, co-
expression of GPA2 and GPB5 has been documented in
various tissues and paracrine roles for thyrostimulin have
been proposed in the pituitary (1, 4, 17), ovary (19), and
skin (20).
Targetedmanipulation ofGPA2 andGPB5 expression
in mice has, thus far, yielded only limited insight into the
physiological role of thyrostimulin. Initial analysis of thy-
rostimulin-deficient animals (GPB5 knockout [KO]) did
not identify an overt phenotype (4, 21). Nevertheless, ju-
venile mutants were subsequently found to have isolated
mild hypothyroxinaemia and abnormal responses to thy-
roidhormonemanipulation (17). By contrast, global over-
expression of GPB5, from the Rosa26 locus, resulted in a
2-fold increase in systemic thyroid hormone levels, resis-
tance todiet-inducedobesity, increasedmetabolic rate and
abnormal skull development (21). Similarly, transgenic
overexpression of GPB5 under control of the metallothio-
nein-1 promoter resulted in a 3-fold elevation of serumT4
and thyroid follicular and adrenocortical cell hyperplasia
(4). This phenotype was replicated in wild-type (WT)
mice, by a once daily ip injection of recombinant GPA2/
GPB5 (4). By contrast, transgenic over expression of
GPA2 resulted in no phenotype (4). Overall, these studies
have been interpreted to indicate that thyrostimulin is not
essential for mammalian development and reproduction,
and that most of the phenotypic consequences of thyro-
stimulin excess are secondary to activation of the thyroid
axis (4, 21).
In summary, the roles of the ancestral glycoprotein hor-
mone “thyrostimulin” and its unique subunits GPA2 and
GPB5 are unknown, and, despite demonstration of TSHR
expression in bone cells (22–24), the skeletal-conse-
quences of GPB5 overexpression remain unexplained
(21).We hypothesized that thyrostimulin exerts paracrine
actions in the skeleton. To investigate this hypothesis we
determined GPA2 and GPB5 expression in primary os-
teoblasts and osteoclasts, analyzed the skeletal phenotype
of thyrostimulin-deficient mice, and determined osteo-
blast and osteoclast responses to thyrostimulin treatment.
Materials and Methods
Cell culture
Mouse osteoblast culture
Primary osteoblasts were prepared from calvariae of postna-
tal day (P)3 C57BL/6mice (25). Osteoblasts were cultured in the
absence or presence of T3 (100nM). Cells were harvested for
RNA extraction on days 6, 9, 12, and 28. Mouse osteoblastic
MC3T3-E1 cells (ATCC CRL-2593) were cultured as described
(26).
Osteoblast proliferation, differentiation and mineralization
experiments were performed using primary mouse calvarial os-
teoblasts seeded at 106 cells/well in  Modified Eagle Medium
(MEM) supplemented with 10% fetal calf serum (FCS), penicil-
lin and streptomycin (PS), -glycerol phosphate (2.5mM), and
L-ascorbic acid (50 g/mL). Cells were treated for 9 or 28 days
with medium alone (control) or supplemented with conditioned
medium fromCOS-7 cells (10% vol/vol) transfected with empty
vector (vector), conditioned medium from COS-7 cells (10%
vol/vol) transfected with GPA2/GPB5 expression vector (GPA2/
GPB5), or with PTH (100M).
Mouse bone marrow stromal cell (BMSC)/osteoblast
culture
Primary BMSC/osteoblast cultures were prepared as de-
scribed (27). Bone marrow was flushed from long bones of
8-week-old C57BL/6 mice and seeded at 500 000 cells/cm2 in
MEM supplemented with 10% FCS containing PS. At 70%
confluence, osteoblast differentiationwas inducedbyadditionof
-glycerol phosphate (5mM) and ascorbate phosphate (50 g/
mL). Osteoblast proliferation, differentiation and mineraliza-
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tion experiments were performed in cells treated for 9 or 28 days
as above.
Human osteoblast culture
Normal human osteoblasts (Clonetics) were seeded at 1 
104 cells/cm2 and cultured until confluent in MEM containing
10% heat-inactivated FCS (HI-FCS) containing PS. Cells were
reseeded at 1 104 cells/cm2 and differentiated in MEM con-
taining HI-FCS (10%) and PS supplemented with hydrocorti-
sone-21-hemisuccinate (200nM), 55-g/mL ascorbic acid and
7.5mM -glycerophosphate (Clonetics) in the absence or pres-
ence of T3 (100nM) at 37°C in 5%CO2.Cellswere harvested for
RNA on days 7, 14, 21, and 28.
Mouse osteoclast culture
Bonemarrowosteoclast progenitorswere prepared fromP35
C57BL/6 mice (24). Bone marrowwas flushed from long bones,
resuspended in MEM containing FCS (10% vol/vol) and M-
CSF (25 ng/mL) (R&D Systems), plated at 1.5  106 cells/mL,
and cultured overnight. Nonadherent cells were replated at 1
106 cells/mL in MEMcontaining FCS (10%), macrophage col-
ony stimulating factor (M-CSF) (25 ng/mL) and receptor acti-
vator of nuclear factor kappa-B ligand (10 ng/mL) (R&D Sys-
tems) and culturedT3 (100nM). Cells were harvested for RNA
on days 6, 9, and 12. Some cultures were stained for tartrate-
resistant acid phosphatase (TRAP) activity (Sigma-Aldrich) to
confirm the presence of osteoclasts.
Human osteoclast culture
A total of 40-mL peripheral blood collected with EDTA was
diluted 1:1 with PBS, and mononuclear cells were isolated using
a LeucoSep centrifuge tube (Greiner bio-one) containing 15 mL
of histopaque (Sigma-Aldrich) according to manufacturer’s in-
structions. Cellswere resuspended inMEMcontainingHI-FCS
(10%), PS,M-CSF (25 ng/mL), and receptor activator of nuclear
factor kappa-B ligand (50 ng/mL) (R&D Systems), plated at 3
106 cells/mL, and cultured overnight. Nonadherent cells were
removed and cultured at 1 106 cells/mLT3 (100nM) at 37°C
in 5%CO2. Cells were harvested for RNAon day 35.Osteoclast
formation was confirmed by TRAP staining.
Chinese hamster ovary (CHO) cell culture
ACHO cell line stably transfected with human TSH receptor
(JP26) and a control cell line with vector alone (JP02) were pro-
vided by Sabine Costagliola (28). Cells were maintained in
Coon’s modification of Ham’s medium (F-12 medium) with L-
glutamine (Invitrogen), supplemented with 10% FCS, PS, and
Geneticin (G418 400 g/mL) (Invitrogen) at 37°C in 5% CO2.
RNA isolation and RT-PCR
Total RNA was extracted using TRIzol (Invitrogen) accord-
ing tomanufacturer’s instructions. Fresh bone sampleswere pul-
verized at 80°C using a steel pestle and mortar (Biospec), the
resulting powder was homogenized in TRIzol and RNA ex-
tracted. RT-PCR was performed using cDNA synthesized with
polyA primers and superscript II reverse transcriptase (Invitro-
gen). A total of 1-g total RNA was denatured at 70°C for 10
minutes, polyA primers and 1 U of superscriptase II were added
and incubated for a further 30 minutes at 42°C. PCR was per-
formed using Platinum Taq DNA polymerase (Invitrogen).
Expression of osteoblast marker genesRunx2, osterix (Osx),
andosteocalcin (Oc)was determined in calvarial osteoblasts and
BMSC/osteoblasts. Cells were lysed in TRIzol and RNA isolated
using an RNeasy kit (QIAGEN). RNA quantity and quality was
determined using a Nanodrop 1000 spectrophotometer
(Thermo Scientific). A total of 750-ng RNA was converted to
cDNA using a Quantitect reverse transcription kit (QIAGEN)
and used for real-time PCR using a KAPA SYBR Fast qPCR kit
(KAPA Biosystems). Reactions were run on a 7900HT real-time
PCR system (Applied Biosystems): 50°C for 2 minutes, 95°C for
10minutes followedby40 cycleswith95°C for30 seconds, 60°C
for 30 seconds, and 72°C for 30 seconds. Samples from 3 inde-
pendent experiments were run in triplicate; results were calcu-
lated by comparison with a standard curve and presented as
arbitrary units relative to 18S rRNA. Primers are detailed in
Supplemental Table 1.
GPB5KO and WT mice
GPB5KO mice (129SvEv background) were generated by
Lexicon Genetics, Inc. Heterozygous GPB5/ mice were
crossed for 3 generations before maintenance of separate WT
and GPB5KO breeding lines (17). Germline transmission of the
knockout allele and genotyping was confirmed by PCR using
specific primers (Common-forward, GCCTGAGACTGCTTT-
GAGGG; WT-reverse, CCACTGCACCAAGGACAAGG; and
GPB5KO-reverse, CTGCCTGACTTCCTCACAGC) (Sigma
REDExtract-N-Amp Tissue PCR kit; Sigma-Aldrich). Animals
were maintained at 22°C with a 12-hour light, 12-hour dark
cyclewith ad libitum food andwater.Male and femaleGPB5KO
andWTmicewere analyzedatP42 (6wk) andP112 (16wk).Tail
lengths were determined during growth and at killing. Mice re-
ceived 2 injections of calcein (15 mg/kg in saline with 2%
NaHCO3) 7 and 4 days before killing. The local animal welfare
committee approved the study, and animalswere treated accord-
ing to ETS123 (Council of Europe) guidelines.
Thyroid function
Serum thyroid hormone levels
Serum T4 and T3 were measured using in-house RIAs, and
TSHwas determined using a double-antibody precipitation RIA
(17).
TRH test
At P42, mice were injected ip with 100-ng TRH (Ferring) in
0.5-mL sterile 0.9% NaCl, or with vehicle (29). Serum was col-
lected before and 20 minutes after TRH administration, and
TSH levels were determined (17).
Histological analysis of the growth plate
Limbs were fixed in 10% neutral buffered formalin for 24
hours and decalcified in 10% EDTA for 5 days. Paraffin-em-
bedded sections were stained with van Gieson and Alcian blue,
and growth plate parameters were determined as described (30).
Images of the proximal tibia were acquired using a Leica DM
LB2 microscope (Leica AG) and DFC320 digital camera. Mea-
surements at 4 locations across the width of growth plates were
obtained using ImageJ (http://rsb.info.nih.gov/ij/) to calculate
mean heights of the reserve, proliferative and hypertrophic
3100 Bassett et al GPB5 Deficiency and Osteoblast Function Endocrinology, September 2015, 156(9):3098–3113
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 28 August 2015. at 03:57 For personal use only. No other uses without permission. . All rights reserved.
zones, and total growth plate. Results from 2 midline levels of
sectioning were compared to ensure data consistency.
Skull microscopy
Skulls from P42 mice were imaged using a Leica MZ75 bin-
ocular microscope, KL1500 light source, and DFC320 digital
camera. Skull dimensions were determined using ImageJ.
Digital x-ray microradiography
Skin and soft tissuewas removed from lower limbs anddigital
x-ray images recorded at 10-m resolution using a Faxitron
MX20 variable kV point projection x-ray source and digital
image system operating at 26 kV and5magnification (Qados,
Cross Technologies plc). Relative mineral content was deter-
mined as described (31). Superior and lateral skulls images were
obtained at 30 kV and dimensions determined using ImageJ.
Micro-computerized tomography (CT) analysis
Long bones were analyzed by micro-CT (Skyscan 1172a;
Bruker) at 50 kV and 200 mA using a 0.5-mm aluminum filter
and a detection pixel size of 4.3 mm2 as described (30, 32).
Trabecular bone parameters (gray level thresholds 85 and 255)
were determined in a 1-mm3 region of interest (ROI) 0.2 mm
from the growth plate (33). Cortical bone parameters (gray level
thresholds 85 and 255) were determined in a 1-mm ROI in the
middiaphysis (33). To generate high-resolution three-dimen-
sional images, 16-bit Tiff images were imported into 32-bit
Drishti (AustralianNational University Supercomputer Facility,
http://anusf.anu.edu.au/Vizlab/drishti/), and ROIs were ren-
dered using 64-bit Drishti.
Back scattered electron (BSE)-scanning electron
microscopy (SEM)
Femurs and tibias were fixed in 70% ethanol, opened longi-
tudinally and macerated as described (34). Samples were coated
with carbon and imaged using backscattered electrons at 20-kV
beampotential in aZeissDSM962digital scanningEMequipped
with an annular solid state BSE detector (KE Electronics).
Quantitative BSE-SEM (qBSE-SEM)
The distribution of mineralization densities within calcified
tissues was examined by BSE-SEM quantified by digital image
analysis at the cubic micron volume resolution scale. Humeri
were fixed in 10% neutral buffered formalin for 24 hours and
transferred to 70% ethanol before embedding in poly-methyl-
methacrylate. Longitudinal block faces were cut through speci-
mens, which were then polished, coated with carbon, and ana-
lyzed using backscattered electrons in a Zeiss DSM962 operated
at 20 kV and 0.5 nA and a 17-mm working distance (11 mm,
sample to detector distance). Themineralization densities of cal-
cified tissues were determined relative to halogenated dimeth-
acrylate standards: C22H25O10Br (mean BSE coefficient 
0.1159) to C22H25O10I (mean BSE coefficient  0.1519).
Increasing gradations of micromineralization density were rep-
resented in 8 equal intervals by a pseudocolor scheme (34).
Confocal microscopy analysis of bone formation
Two-dimensional parameters of bone formation were deter-
mined according to the American Society for Bone and Mineral
Research system of nomenclature (35). Midline longitudinal
block faces were cut through poly-methyl-methacrylate-embed-
ded long bones. Specimens were polished to an optically flat
finish and examined using confocal autofluorescence scanning
light microscopy (CSLM) of calcein labels to determine the frac-
tion of bone surface undergoing active bone formation (n 3–5
mice per genotype, per gender).ALeica SP1 confocalmicroscope
using 488-nm excitation and 40/1.25 objectives generated
combined reflection (blue), calcein fluorescence (green), and au-
tofluorescence (red) CSLM images (30). Tissue layers immedi-
ately deep to the block surface were visualized to ensure only
fluorescently labeled bone-forming surfaces that lie in orthogo-
nal planes were analyzed. The mineral apposition rate (MAR)
was calculated by determining calcein separation at 10–20 lo-
cations per specimen. Montages were generated, and the bone
and mineralizing surfaces measured using ImageJ (30). Mon-
tages of 20 (magnification 40) overlapping CSLM fields were
constructed for each bone. Trabecular and endosteal bone sur-
faces were determined using ImageJ. Mineralizing surface and
MAR were determined by quantifying calcein-labeled surfaces
and the mean separation between calcein double labels. Bone
formation rate (BFR) was calculated from the product of min-
eralizing surfaces andMAR.Measurements commenced200m
(trabecular bone) and 2 mm (cortical bone) below the growth
plate (30).
Osteoclast histomorphometry
Osteoclast numbers were determined according to the Amer-
ican Society for Bone and Mineral Research system (35) in par-
affin sections stained for TRAP activity using a Sigma TRAP kit
(386A-1KT) according to manufacturer’s instructions. For each
sample sections from 2 separate levels (n  2 slides) were pho-
tographed at100 magnification using a Leica DMLB2 micro-
scope and DFC320 digital camera, and a 750  750-m ROI
commencing 250 m below the growth plate was analyzed. Os-
teoclast numbers per bone perimeter (Oc.N/B.Pm), osteoclast
perimeter (Oc.Pm), and osteoclast surface per bone perimeter
(Oc.S/B.Pm) were determined in trabecular bone (n 3–5 mice
per genotype, per gender) andnormalized to total boneperimeter
(B.Pm) (30). The fraction of the bone surfaces that displayed
osteoclastic bone resorption was quantified in high-resolution
BSE-SEM images (30).
Destructive 3-point bend testing
Bones were stored and tested in 70% ethanol. Destructive
3-point bend tests were performed using an Instron 5543 load
frame and 100N load cell (Instron). Humeri were positioned
horizontally on custom supports and load was applied perpen-
dicular to the middiaphysis with a constant rate of displacement
of 0.03mm/s until fracture. Yield load, maximum load, fracture
load, and stiffness were determined from load displacement
curves (30, 32).
Expression of GPA2/GPA5
Gpa2 and Gpb5 expression vectors
Full-lengthGpa2andGpb5cDNAswere amplified fromtotal
mouse brain RNA by RT-PCR using primers mGPA2F, GACT-
GTCCTTTGCAGATGCCC and murine GPA2R, AGC-
CCCGAGTTTGAGATACCC forGpa2 and primers mGPB5F,
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AGCCTGGGGTACAAGTGTCAGC and mGPB5R, TG-
GAGCCAGTGGATGTGTGAG for Gpb5. The Gpa2 and
Gpb5 cDNAswere subcloned intopGEM-TEasy (Promega) and
sequenced (36). GPA2 and GPB5 subunits were either coex-
pressed or expressed individually using the bicistronic vector
pBudCE4.1 (Invitrogen): 1) Gpa2 was subcloned into the
pBudCE4.1 using theNotI andXhoI sites resulting in expression
of aHis-V5-tagged GPA2 protein (GPA2-His-V5), 2)Gpb5was
subcloned into pBudCE4.1 using the HindIII and BamHI sites
resulting in expression of a hemagglutinin (HA)-tagged GPB5
protein (GPB5-HA), and 3) both Gpa2 and Gpb5 were sub-
cloned into pBudCE4.1 (GPA2-His-V5GPB5-HA).
Transient transfection of Cos-7 cells
5  106 Cos-7 cells were cultured overnight in DMEM (In-
vitrogen), 10% HI-FCS, containing PS. Cells were transfected
with 1) GPA2-His-V2, 2) GPB5-HA, 3) GPA2-His-V2GPB5-
HA,or4) pBudCE4.1vector aloneusing theLipofectamine2000
reagent (Invitrogen) according to manufacturer’s instructions
and cultured for 72 hours. Medium was concentrated 20-fold
using a centrifugal filter and cell lysates prepared in radioimmu-
noprecipitation assay buffer (Sigma-Aldrich).
Western blot analysis
Medium and cell lysates were subjected to SDS-PAGE.Mem-
branes were blocked with fat-free milk (5%) with Tween (1%)
for 1 hour and incubated overnight at 4°C in the presence of
either a monoclonal mouse anti-V5 (Sigma-Aldrich) or anti-HA
(Invitrogen) antibody. Blots were visualized using a goat anti-
mouse horseradish peroxidase-conjugated antibody and Super-
Signal West Femto enhanced chemiluminescent substrate
(Thermo Scientific) according to manufacturer’s instructions.
Conditioned media were deglycosylated using N-glycosidase F
(New England Biolabs) or covalently cross-linked with disuc-
cinimidyl suberate (Sigma-Aldrich), according to manufactur-
er’s instructions, and the products analyzed byWestern blotting.
cAMP immunometric assay
cAMP assays were performed in confluent JP02 and JP26
CHO cells. Medium was replaced with Krebs-Ringer HEPES
(KRH) buffer, and cells were incubated for 30 minutes at 37°C.
KRH buffer was replaced with 1) KRH containing rolipram
(25M) (Sigma), which prevents degradation of cAMP; 2) KRH
containing rolipram (25M) and forskolin (10M) (Sigma); 3)
KRH containing rolipram (25M) and human TSH (hTSH)
(0.001, 0.01. and 0.1 U/L); or 4) conditioned media from Cos-7
cells transfectedwith the various constructs (500L) containing
rolipram (25M). Cells were incubated at 37°C for 1 hour, me-
dium was removed, and cells were lysed with 0.1M HCl for 20
minutes. cAMP was quantified in 100 L of cell lysate using
cAMP EIA kit (Stressgen Biotechnologies Corp) following man-
ufacturer’s instructions.
Noncanonical TSHR signaling pathway analyses
Activation of noncanonical signaling pathways was deter-
mined in cells cultured for 9 or 28 days. Cells were incubated in
serum-free MEM overnight before treatment for 5, 15 or 30
minuteswith1)MEMmediumcontrol, 2) conditionedmedium
from COS-7 cells transfected with empty vector (20% vol/vol),
or 3) conditioned medium from COS-7 cells transfected with
GPA2/GPB5 (20% vol/vol). Cells were lysed and the concen-
trations of phospho-AKT, phospho-ERK, and phospho-mi-
togen-activated protein kinase (P38) (P38MAPK) determined
according to the manufacturer’s instructions (Surveyor IC
phospho-kinase immunoassay kits [SUV887B, SUV1018B,
SUV869B]; R&D Systems).
Osteoblast proliferation, differentiation, and miner-
alization assays
The number of viable osteoblasts was determined using the
alamarBlue assay (LifeTechnologies).Osteoblast differentiation
was quantified by alkaline phosphatase (ALP) activity normal-
ized to cell number: cells were homogenized in 1M diethanol-
amine, 1mMMgCl2, 0.05%TritonX-100, the lysate wasmixed
with an equal volume of paranitrophenol-phosphate (20mM)
and absorbance measured at 414 nm.Mineralization was deter-
mined by alizarin red staining: cells were fixed in 70% ethanol,
stained for 20 minutes in 40mM alizarin red (pH 4.2), and
destained for 15 minutes with acetylpyridinium chloride (10%
wt/vol in 10mMNa3PO4). Absorbance of extracted alizarin red
was measured at 562 nm and normalized to cell number.
Statistics
Normally distributed data were analyzed by Student’s t test
and nonparametric data by the Mann-Whitney U test. P  .05
was considered significant. Frequency distributions of bonemin-
eral densities obtained by Faxitron and qBSE-SEM were com-
pared using the Kolmogorov-Smirnov test (30, 37).
Results
Expression of TSH, thyrostimulin, and TSHR in
bone
Expression of bothGpa2 andGpb5mRNAswas read-
ily identified in skulls and long bones from newborn WT
mice. Expression ofGpa2was reduced by P14 and barely
detectable at P28, whereas expression of Gpb5 was only
present in skulls at P14 but was absent from both skulls
and long bones at P28 (Figure 1A). Neither CGA nor
TSHB mRNAs (encoding the - and -subunits of TSH,
the established hormone that binds and activates TSHR)
were expressed in mouse or human primary osteoblast or
osteoclast cultures (Figure 1, B and C).TSHRmRNAwas
expressed in mouse and human osteoblasts and mouse
osteoclasts but was at the limit of detection in human os-
teoclasts.GPA2was expressed in bothmouse and human
osteoblasts and osteoclasts. Four distinct human GPA2
RT-PCR products were amplified from brain mRNA but
only 2 were expressed in osteoblasts and osteoclasts. Se-
quencing revealed the size differences resulted from reten-
tionof intron2 (182bp), intron3 (116bp), or both introns
2 and 3 (Supplemental Figure 1A). Inclusion of intron 2
results in an open reading frame terminated by a stop
codon after 93 bp, whereas inclusion of intron 3 results in
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anopen reading frame terminated by
a stop codon after 69 bp. TheGPA2
mRNAs expressed in human osteo-
blasts and osteoclasts consisted of
the full-length correctly spliced
GPA2 mRNA (283 bp) and an un-
spliced transcript (581 bp), in which
introns 2 and 3 are retained (Supple-
mental Figure 1A). By contrast,
Gpb5was expressed only at low lev-
els early indifferentiation inmouseos-
teoblasts but was not detected in
mouse osteoclasts (Figure 1B), whereas
GPB5 mRNA expression was clearly
detectable inhumanosteoblasts andos-
teoclasts (Figure 1C).
An alternative spice variant of
Tshb (Tshb-sv) that includes a27nu-
cleotide portion of intron 4 adjoin-
ing the coding region of exon 5 has
been previously identified in mouse
(Figure 2B) but not human bone
marrow and has also been shown
to stimulate a cAMP response in
TSHR-expressing cells in vitro (38–
41). The Tshb-sv isoform was pres-
ent at low levels in primary mouse
osteoblasts but not in osteoclasts
(Figure 1B). Notably, this 27bp se-
quencehasonly limited conservation
between species (Supplemental Fig-
ure 1, C and D).
T3 treatment did not affect expres-
sionofCGA,TSHB,TSHR,GPA2,or
GPB5 in either human or mouse pri-
mary cultures, suggesting that effects
of T3 on bone are not mediated via
modulation of TSHR signaling.
Analysis of thyrostimulin-
deficient mice
Having demonstrated that both
subunits of thyrostimulin (GPA2
andGPB5) were expressed in whole
bone but variably expressed in skel-
etal cells, we next investigated the
physiological role of thyrostimulin
during skeletal development and in
adult bone by determining the con-
sequences of thyrostimulin defi-
ciency in mice lacking Gpb5
(GPB5KO).
Figure 1. Mouse and human GPA2, GPB5, CGA, TSHB, and TSHR mRNA expression. A, Gpa2
and Gpb5 mRNA, and 18s rRNA, expression in skeletal and nonskeletal mouse tissues during
development at P1, P14, and P28. ve ctrl, no reverse transcriptase control. B, Cga, Tshb, Tshr,
Gpa2, and Gpb5 mRNA expression in mouse primary osteoblasts and osteoclasts cultured in the
presence or absence of 100nM T3. C, CGA, TSHB, TSHR, GPA2, and GPB5 mRNA expression in
human primary osteoblasts and osteoclasts in the presence or absence of 100nM T3.
Noncontiguous lanes are separated by a white line. Cga, glycoprotein hormones, ; Tshb, TSH;
Tshb-sv, TSH splice variant; Tshr, TSHR; Gpa2, glycoprotein hormone 2; Gpb5, glycoprotein
hormone 5.
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Systemic thyroid status in thyrostimulin-deficient
mice
At P42, there was no difference in thyroid status be-
tween female WT and GPB5KO mice, whereas male
GPB5KO mice had a 3-fold increase (P  .01) in circu-
lating TSH, a 35% lower T4 (P  .06), but a normal T3
concentration compared with WT. Nevertheless, admin-
istration ofTRHresulted in similar TSH responses in both
WTandmutant animals. Adult female andmaleGPB5KO
mice were euthyroid (Figure 2).
Increased bone mineral content (BMC), volume,
and mineralization in juvenile thyrostimulin-
deficient mice
Normal ossification and linear growth
Growth plate architecture and reserve, proliferative
and hypertrophic zone dimensions did not differ between
WT and GPB5KOmice at P42 (Supplemental Figure 2, A
andB). Furthermore, linear growthvelocity and final bone
length were similar among male and female WT and
GPB5KOmice (Supplemental Figure2C).Decreasednasal
and frontal bone length has previously been described in
transgenic mice overexpressing GPB5 (21). However, no
differences in skull morphology or dimensions were ob-
served in thyrostimulin-deficient mice (Supplemental Fig-
ure 3).
Increased BMC, volume, and mineralization
Digital x-ray microradiography demonstrated in-
creased BMC in juvenile GPB5KO mice compared with
WT, and this difference was greater in males than females
(Figure 3). Micro-CT and qBSE-SEM analyses were per-
formed to determine whether the increased BMC was a
consequence of increased bone volume, increased bone
mineralization, or both.
Micro-CT analysis of femurs from juvenile animals
demonstrated increased trabecular bone volume, number
and connectivity, reduced trabecular spacing and more
plate-likemorphology inmale GPB5KOmice (Figure 4, A
and B). Trabecular bone parameters did not differ in fe-
male GPB5KO mice compared with WT. Juvenile male
GPB5KOmice also had increased cortical bone area, vol-
ume and thickness but no differences were seen in females
(Figure 4, C and D). Cortical bone porosity did not differ
in juvenile GPB5KOmice of either gender compared with
WT(male1.150.04%vs1.070.13%,P .59; female
Figure 2. Serum thyroid hormone and TSH levels. A and B, Serum T4, T3, and TSH levels in female and male juvenile (P42) and adult (P112) WT
and GPB5KO mice (mean  SEM for T4 and T3; individual values, median, and interquartile range for TSH). Mann-Whitney U test; #, P  .05: ##,
P  .01 GPB5KO vs WT (n  4–9 per genotype per age). nd, not determined because insufficient sample. C, Serum TSH response to TRH (100 ng
ip) in female and male juvenile (P42) WT and GPB5KO mice. Mann-Whitney U test; #, P  .05 response to TRH; GPB5KOTRH vs WTTRH not
significant (n  6–8 per genotype).
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0.19  0.04% vs 0.40  0.13%, P  .19). qBSE-SEM
demonstrated increased trabecular bonemineralization in
juvenile femaleGPB5KOmice and increased cortical bone
mineralization in juveniles of both genders (Figure 5).
Increased osteoblastic bone formation
Static and dynamic histomorphometry was performed
to investigate the cellular basis underlying the increased
bone volume and mineralization in juvenile GPB5KO
mice.Bone formationparametersweredetermined in sam-
ples from calcein double-labeled mice (Figure 6A). In ju-
venile female GPB5KO mice MAR (double calcein label
separation divided by time between administration of la-
bels) was increased by 26% and BFR (MARmultiplied by
length of mineralizing surface) by 55%. In juvenile male
GPB5KO mice, mineralizing surfaces were increased
27%, and BFR showed a similar trend to females. By con-
trast, osteoclastic bone resorption parameters did not dif-
fer among GPB5KO and WT mice (Figure 6B).
Normal bone strength and stiffness
Three-point bend testing was performed to charac-
terize the functional consequences of thyrostimulin
deficiency. Despite the increase in
cortical bone thickness and mineral-
ization in GPB5KO mice, biome-
chanical parameters (yield load,
maximum load, fracture load, and
stiffness) did not differ fromWT an-
imals (Supplemental Figure 4).
Normalization of the skeletal
phenotype in adult
thyrostimulin-deficient mice
In contrast to the juvenile skeletal
phenotype, adult GPB5KOmice had
similar BMC to WT (Supplemental
Figure 5). Minor increases in trabec-
ular number and bone volume per
tissue volume (BV/TV) were evident
in females (P  .05 both parame-
ters), and a small increase in cortical
bone area (Ct.Ar/Tt.Ar) was present
in males (P  .05). All other trabec-
ular and cortical bone parameters
did not differ between WT and
GPB5KOmice of both genders (Sup-
plemental Figure 6). Consistent with
this, cortical bone porosity did not
differ in adult GPB5KO mice com-
pared withWT (male 0.70 0.29%
vs 1.10  0.09%, P  .23; female
0.30 0.33%vs 0.44 0.22%,P
.61). BSE-SEM analysis of long bone microarchitecture
was consistentwith these x-raymicroradiography andmi-
cro-CT findings (Supplemental Figure 7). In qBSE-SEM
studies, only a small increase (P  .05) in cortical bone
mineralization density was observed in adult female
GPB5KO mice, whereas a small decrease (P  .05) was
present in males (Supplemental Figure 8). In accord, bone
formation and resorption parameters, and bone strength
were similar among adult GPB5KO and WT mice (Sup-
plemental Figures 4 and 9).
In summary, comprehensive skeletal phenotyping of
GPB5KOmice using complementary approaches revealed
that thyrostimulin deficiency results in a developmental
phenotype characterized by a transient increase in bone
formation and bone mass. Importantly, these abnormal-
ities resolve by adulthood.
TSH and thyrostimulin signaling in bone cells
To investigate the molecular mechanisms underlying
the skeletal abnormalities identified in juvenile GPB5KO
mice, themurineGPA2 andGPB5 subunits of thyrostimu-
lin were expressed in COS-7 cells (Supplemental Figure
Figure 3. X-ray microradiography. A, Gray scale and pseudocolored images of femurs from P42
WT and GPB5KO mice. The gray scale pixel distribution was stretched between 0 and 256 levels
relative to polyester, aluminum, and steel standards. Gray scale images were divided into 16
equal intervals, each represented by a different color to aid visual presentation of digital images.
In these pseudocolored images, low mineral content is green and high mineral content pink. B,
Relative frequency histograms of bone mineralization densities in which the gray scale pixel
distribution is shown in relation to each of the 16 equally sized color bins (n  4–6 per
genotype, each gender). Kolmogorov-Smirnov test, GPB5KO vs WT; **, P  .01; ***, P  .001.
Scale bar, 1000 m.
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10A). Both GPA2 and GPB5 sub-
units were glycosylated and secreted
into the medium, forming GPA2/
GPB5 heterodimers and GPB5 ho-
modimers (Supplemental Figure 10,
B–D). Conditioned medium from
COS-7 cells coexpressing GPA2 and
GPB5, but not expressing GPA2 or
GPB5 alone, induced a large cAMP
response in TSHR-expressing CHO
cells but no response in TSHR-defi-
cient cells (Supplemental Figure
10E). Nevertheless, and despite
strong cAMP responses to forskolin,
neither hTSHnor thyrostimulin elic-
ited a cAMP response in mouse pri-
mary osteoblasts, MC3T3 cells or
mouse primary osteoclasts. Thus, in
these studies cAMP responses to
hTSH and thyrostimulin in osteo-
blasts and osteoclasts did not differ
from controls (Supplemental Figure
10F).
To investigate whether thyro-
stimulin directly inhibits calvarial
osteoblast function, cell prolifera-
tion, differentiation, andmineraliza-
tion assays were performed (Figure
7). Primary calvarial osteoblasts
were cultured for9and28days in the
presence of conditioned medium
from COS-7 cells transfected with
vector alone or with medium from
cells coexpressing GPA2 and GPB5.
Continuous treatment with PTH
was used as a positive control for in-
hibition of osteoblast activity. Thy-
rostimulin had no effect on the num-
ber of viable osteoblasts, ALP
activity or nodule formation and
mineralization at both time points
(Figure 7, A–D) and did not affect
levels of expression of Runx2, Osx,
or Oc osteoblast marker gene
mRNAs (Figure 7E). Persisting thy-
rostimulin activity was confirmed in
the conditioned medium at comple-
tion of the 28-day culture period by
determining the cAMP response in
TSHR-expressing CHO cells (data
not shown). To investigate whether
thyrostimulin activates noncanoni-
Figure 4. Micro-CT. A, Micro-CT images of the distal femoral metaphysis from P42 WT and
GPB5KO mice. B, Graphs showing BV/TV, trabecular number (Tb.N), trabecular thickness (Tb.Th),
trabecular spacing (Tb.Sp), structure model index (SMI) (an indicator of trabecular shape, in
which pure rod-like shape  3, pure plate-like  0), and connectivity density (Conn.D) (mean 
SEM) in distal femur trabecular bone from P42 WT and GPB5KO mice. C, Micro-CT images of the
middiaphyseal femur cortical bone from P42 WT and GPB5KO mice. D, Graphs showing total
cross-sectional area of cortical bone inside the periosteal envelope (Tt.Ar), cortical bone area
(Ct.Ar), cortical area fraction (Ct.Ar/Tt.Ar), cortical BV, cortical bone volume fraction (BV/TV), and
average cortical thickness (Ct.Th) (mean  SEM) in middiaphyseal femur from P42 WT and
GPB5KO mice. Student’s t test, GPB5KO vs WT; *, P  .05; **, P  .01 (n  3 per genotype, per
gender). Scale bars, 200 m.
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cal TSHRdownstream signaling pathways in calvarial os-
teoblasts, analysis of the Akt, ERK, and P38 (P38MAPK)
pathways was performed (Figure 7, F–I). Thyrostimulin
had no effect on these downstream pathways in cells cul-
tured for 9 or 28 days.
To investigate further whether the effects of thyro-
stimulin on bone formation are likely to be mediated by
primary actions on osteoblast precursor cells, studieswere
also performed inBMSC/osteoblasts cultured for 9 and28
days (Figure 8). Thyrostimulin had no effect on the num-
ber of viable BMSC osteoblasts, ALP activity, nodule for-
mation, mineralization or marker gene expression at both
time points (Figure 8, A–E). Thyrostimulin also had no
effect on noncanonical TSHRdown-
stream signaling pathways (Figure 8,
F–I), although there was a trend for
inhibition ofAKTactivation after 30
minutes treatment (P  .051) in
day-28 BMSC osteoblasts (Figure
8G, right panel).
Discussion
During postnatal skeletal develop-
ment the ancestral glycoprotein hor-
mone subunitsGpa2 andGpb5were
transiently expressed in long bones
(formed by endochondral ossifica-
tion) and the skull (formed by in-
tramembranous ossification). How-
ever, the levels of Gpa2 and Gpb5
mRNAs were variable in cultured
osteoblasts and osteoclasts, whilst
currently available antibodies were
not sufficiently sensitive or specific
to determine expression of GPA2
and GPB5 proteins (data not
shown).
Consistentwith the transient skel-
etal expression of thyrostimulin dur-
ing early postnatal development, the
abnormal phenotype in juvenile
GPB5KO mice resolved by early
adulthood. Skeletal findings in
GPB5KOmice were restricted to ab-
normalities of bone formation and
mineralization, demonstrating a pri-
mary role for thyrostimulin in the
regulation of osteoblast activity. Im-
portantly, linear growth and long
bone modeling and morphology
were unaffected in GPB5KO mice,
indicating that thyrostimulin deficiency does not affect
chondrocyte or osteoclast function.
Comprehensive analysis of the skeleton using comple-
mentary techniques revealed similar phenotypes in males
and females, with small temporal differences observed be-
tween genders. In juvenile GPB5KOmice, trabecular and
cortical bone mass were increased in males but not fe-
males. Females, however, displayed a higher BFR and in-
creased trabecular bonemineralization at a young age but
had increased trabecular bone volume persisting to adult-
hood. Previous studies did not determine thyroid status
separately in males and females but showed that juvenile
Figure 5. Bone micromineralization. A, qBSE-SEM gray scale and pseudocolored images of
metaphyseal trabecular bone from P42 WT and GPB5KO mice. The gray scale pixel distribution
was stretched between 0 and 256 levels relative to halogenated dimethacrylate standards as
indicated in Materials and Methods. Gray scale images were divided into 8 equal intervals, each
represented by a different color to aid visual presentation of digital images. In these
pseudocolored images, low mineralization density is yellow and high density is gray. Graphs
show relative frequency of micromineralization densities in which the gray scale pixel distribution
is shown in relation to each of the 8 equally sized color bins. B, qBSE-SEM images and relative
frequency histograms from middiaphyseal cortical bone in P42 mice. Kolmogorov-Smirnov test,
GPB5KO vs WT; **, P  .01; ***, P  .001 (n  3–5 per genotype, each gender). Scale bars,
200 m.
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GPB5KO mice have transient hypothyroxinemia with a
compensatory increase in TSH (17). In the current studies,
juvenile female GBP5KOmice and adults of both genders
were euthyroid, whereas juvenile males had a trend for
hypothyroxinaemia (P .06)with an increased TSH. The
similar TSH response to TRH in juvenile GPB5KO and
WTmice revealed intact pituitary thyrotroph responsive-
ness in GPB5KO mice, suggesting that the transient hy-
Figure 6. Dynamic and static histomorphometry. A, Confocal laser scanning microscopy (CLSM) images of calcein double labeled trabecular bone
from P42 WT and GPB5KO mice. Scale bar, 50 m. Two-dimensional quantitative analysis of mineralizing perimeter (MS/B.Pm), MAR, and BFR
(BFR/B.Pm) (mean  SEM). B, Proximal tibia trabecular bone sections from P42 WT and GPB5KO mice stained for TRAP activity. Arrows indicate
TRAP positive osteoclasts. Scale bar, 100 m. Two-dimensional quantitative analysis of the trabecular B.Pm, Oc.S/B.Pm, Oc.N/B.Pm, and the mean
osteoclast perimeter (Oc.Pm). Student’s t test, GPB5KO vs WT; *, P  .05; **, P  .01 (n  3–5 per genotype, per gender, per age).
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Figure 7. TSHR signaling in primary calvarial osteoblasts. A, Primary mouse osteoblasts treated for 28 days with medium (control), medium
supplemented with conditioned medium from COS-7 cells (10% vol/vol) transfected with empty vector (vector), medium supplemented with
conditioned medium from COS-7 cells (10% vol/vol) transfected with GPA2/GPB5 expression vector (GPA2/GPB5), and PTH (100M). B, Graphs
showing analysis of osteoblast proliferation (viable cells, %) after 9 and 28 days in response to treatments. C, Graphs showing analysis of
osteoblast differentiation (ALP activity) after 9 and 28 days in response to treatments. D, Graphs showing analysis of osteoblast mineralization
(alizarin red staining) after 9 and 28 days in response to treatments. (E) Graphs showing analysis of osteoblast gene expression (Runx2, Osx, and
Oc) after 9 and 28 days in response to treatments. F, cAMP responses of primary osteoblasts cultured for 9 and 28 days after no treatment (OB) or
in response to treatment with forskolin, conditioned medium from COS-7 cells (10% vol/vol) transfected with empty vector (vector), or
conditioned medium from COS-7 cells (10% vol/vol) transfected with GPA2/GPB5 expression vector GPA2/GPB5. G–I, Analysis of noncanonical
TSHR downstream signaling pathways in response to treatment with thyrostimulin (GPA2/GPB5) for 5, 15, and 30 minutes after 9 and 28 days:
(G) Akt pathway activation determined by quantitation of phospho-Akt (pAkt); ve control, MEM medium alone; ve control, recombinant
pAkt2; (H) ERK pathway activation determined by quantitation of phospho-ERK (pERK); ve control, MEM medium; ve control, recombinant
pERK2; (I) P38 pathway activation determined by quantitation of phospho-P38 (pP38); ve control, MEM medium; ve control, recombinant
pP38.
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Figure 8. TSHR signaling in BMSC/osteoblast cultures. A, Primary mouse BMSC osteoblasts treated for 28 days with medium (control), medium
supplemented with conditioned medium from COS-7 cells (10% vol/vol) transfected with empty vector (vector), medium supplemented with
conditioned medium from COS-7 cells (10% vol/vol) transfected with GPA2/GPB5 expression vector (GPA2/GPB5), and PTH (100M). B, Graphs
showing analysis of cell proliferation (viable cells, %) after 9 and 28 days in response to treatments. C, Graphs showing analysis of osteoblast
differentiation (ALP activity) after 9 and 28 days in response to treatments. D, Graphs showing analysis of osteoblast mineralization (alizarin red
staining) after 9 and 28 days in response to treatments. E, Graphs showing analysis of osteoblast gene expression (Runx2, Osx, and Oc) after 9 and
28 days in response to treatments. F, cAMP responses of primary BMSC osteoblasts cultured for 9 and 28 days after no treatment (OB) or in
response to treatment with forskolin, conditioned medium from COS-7 cells (10% vol/vol) transfected with empty vector (vector), or conditioned
medium from COS-7 cells (10% vol/vol) transfected with GPA2/GPB5 expression vector GPA2/GPB5. G–I, Analysis of noncanonical TSHR
downstream signaling pathways in response to treatment with thyrostimulin (GPA2/GPB5) for 5, 15, and 30 minutes after 9 and 28 days: (G) Akt
pathway activation determined by quantitation of phospho-Akt (pAkt); ve control, MEM medium alone; ve control, recombinant pAkt2; (H)
ERK pathway activation determined by quantitation of phospho-ERK (pERK); ve control, MEM medium; ve control, recombinant pERK2; (I) P38
pathway activation determined by quantitation of phospho-P38 (pP38); ve control, MEM medium; ve control, recombinant pP38.
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pothyroxinemia in males is a consequence of altered thy-
roid hormone synthesis or metabolism.
Overall, the skeletal consequences of thyrostimulin de-
ficiency appear to occur earlier and resolve more rapidly
in males than females, and it is important to consider
whether this may result in part from gender differences in
systemic T4 concentrations. Importantly, impaired chon-
drocyte differentiation and linear growth are themost sen-
sitive markers of reduced thyroid hormone action in the
developing skeleton (34, 37, 42, 43) and juvenile hypo-
thyroidism also results in decreased osteoblastic bone for-
mation, reduced bone volume and impaired bone miner-
alization (34, 37, 42). Because growth parameters were
unaffected in GPB5KOmice, and osteoblast function was
increased rather than decreased, the reduction in T4 ob-
served in males during growth is unlikely to contribute to
the skeletal abnormalities observed. Furthermore, similar
skeletal abnormalitieswere observed in euthyroid juvenile
females, emphasizing the phenotype is independent of al-
tered systemic thyroid status. By contrast, the increased
osteoblastic bone formation, bone volume, and mineral-
ization observed in juvenile GBP5KO mice correlates
closely with the transient expression of thyrostimulin in
the developing skeleton. Together, these considerations
identify thyrostimulin as a negative regulator of osteo-
blastic bone formation during skeletal development.
To determine the mechanism of thyrostimulin action
we coexpressed recombinant GPA2 and GPB5 subunits
and generated functionally active thyrostimulin, which
potently activated a canonical cAMP response in TSHR-
expressing CHO cells. However, thyrostimulin, GPA2,
GPB5, or TSH all failed to activate cAMP in osteoblasts
and osteoclasts despite expression of the TSHR. The lack
of response to TSH is consistentwith previous studies (23,
24, 44), but we now demonstrate that even thyrostimulin,
a 4-foldmorepotent ligand forTSHR, also fails to activate
cAMP inosteoblasts andosteoclasts.Wenext investigated
whether thyrostimulin acts via noncanonical TSHR sig-
naling pathways in calvarial osteoblasts and BMSC-de-
rived osteoblast precursors. In both cell types, thyrostimu-
lin failed to activate Akt, ERK or P38 and did not affect
osteoblast proliferation, differentiation,mineralization or
marker gene expression. Overall, these data demonstrate
the effects of thyrostimulin on bone formation are indirect
and not cell autonomous in osteoblast precursor cells or
mature osteoblasts.
In conclusion, these studies demonstrate a transient
role for thyrostimulin during early skeletal development.
The predicted limited stability of GPA2/GPB5 het-
erodimers when compared with other glycoprotein hor-
mones (18) suggests these actions are local rather than
systemic, although the cellular origin and target cells of
thyrostimulin in bone remain uncertain. Nevertheless,
similar transient developmental effects of thyrostimulin
have been suggested in other tissues (1, 4, 17, 19, 20) and
species (5, 15–17), indicating that this ancient glycopro-
tein may have diverse developmental roles in both verte-
brates and nonvertebrates. Importantly, both thyrostimu-
lin and the TSHR are expressed in bone and the current
studies indicate that thyrostimulin has retained a devel-
opmental function but its actions are dispensable in the
adult skeleton. Consistent with such a role, activation of
TSHR signaling has been implicated in self-renewal, dif-
ferentiation, and survival of various progenitor and stem
cell populations (45–49). Overall these considerations
suggest a possible role for thyrostimulin in the regulation
of tissue development and repair. Future studies will be
required to investigate this novel field.
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